News | December 12, 2022
Merck begins Tender Offer to acquire Imago BioSciences
As a result, Imago will become a subsidiary of Merck.
As a result, Imago will become a subsidiary of Merck.
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Acquisition expands Merck’s growing hematology portfolio
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
Subscribe To Our Newsletter & Stay Updated
